<!DOCTYPE html> <html lang="en"> <head> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8"> <meta charset="utf-8"> <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no"> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <title> Ashkan Pirmani </title> <meta name="author" content="Ashkan Pirmani"> <meta name="description" content="Welcome to my personal portfolio, lets learn more about my work and passions. "> <meta name="keywords" content="jekyll, jekyll-theme, academic-website, portfolio-website"> <link rel="stylesheet" href="/assets/css/bootstrap.min.css?a4b3f509e79c54a512b890d73235ef04"> <link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/mdbootstrap@4.20.0/css/mdb.min.css" integrity="sha256-jpjYvU3G3N6nrrBwXJoVEYI/0zw8htfFnhT9ljN3JJw=" crossorigin="anonymous"> <link defer rel="stylesheet" href="/assets/css/academicons.min.css?f0b7046b84e425c55f3463ac249818f5"> <link defer rel="stylesheet" href="/assets/css/scholar-icons.css?62b2ac103a88034e6882a5be5f3e2772"> <link defer rel="stylesheet" type="text/css" href="https://fonts.googleapis.com/css?family=Roboto:300,400,500,700|Roboto+Slab:100,300,400,500,700|Material+Icons&amp;display=swap"> <link defer rel="stylesheet" href="/assets/css/jekyll-pygments-themes-github.css?591dab5a4e56573bf4ef7fd332894c99" media="" id="highlight_theme_light"> <link rel="shortcut icon" href="data:image/svg+xml,&lt;svg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20100%20100%22&gt;&lt;text%20y=%22.9em%22%20font-size=%2290%22&gt;%E2%9A%9B%EF%B8%8F&lt;/text&gt;&lt;/svg&gt;"> <link rel="stylesheet" href="/assets/css/main.css?d41d8cd98f00b204e9800998ecf8427e"> <link rel="canonical" href="https://ashkan-pirmani.github.io//"> <script src="/assets/js/theme.js?9a0c749ec5240d9cda97bc72359a72c0"></script> <link defer rel="stylesheet" href="/assets/css/jekyll-pygments-themes-native.css?5847e5ed4a4568527aa6cfab446049ca" media="none" id="highlight_theme_dark"> <script>
    initTheme();
  </script> </head> <body class="fixed-top-nav "> <header> <nav id="navbar" class="navbar navbar-light navbar-expand-sm fixed-top" role="navigation"> <div class="container"> <button class="navbar-toggler collapsed ml-auto" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation"> <span class="sr-only">Toggle navigation</span> <span class="icon-bar top-bar"></span> <span class="icon-bar middle-bar"></span> <span class="icon-bar bottom-bar"></span> </button> <div class="collapse navbar-collapse text-right" id="navbarNav"> <ul class="navbar-nav ml-auto flex-nowrap"> <li class="nav-item active"> <a class="nav-link" href="/">about <span class="sr-only">(current)</span> </a> </li> <li class="nav-item "> <a class="nav-link" href="/projects/">projects </a> </li> <li class="nav-item "> <a class="nav-link" href="/publications/">publications </a> </li> <li class="nav-item "> <a class="nav-link" href="/repositories/">repositories </a> </li> <li class="nav-item "> <a class="nav-link" href="/teaching/">teaching </a> </li> <li class="nav-item "> <a class="nav-link" href="/cv/">cv </a> </li> <li class="nav-item"> <button id="search-toggle" title="Search" onclick="openSearchModal()"> <span class="nav-link">ctrl k <i class="ti ti-search"></i></span> </button> </li> <li class="toggle-container"> <button id="light-toggle" title="Change theme"> <i class="ti ti-sun-moon" id="light-toggle-system"></i> <i class="ti ti-moon-filled" id="light-toggle-dark"></i> <i class="ti ti-sun-filled" id="light-toggle-light"></i> </button> </li> </ul> </div> </div> </nav> <progress id="progress" value="0"> <div class="progress-container"> <span class="progress-bar"></span> </div> </progress> </header> <div class="container mt-5" role="main"> <div class="post"> <header class="post-header"> <h1 class="post-title"> <span class="font-weight-bold">Ashkan</span> Pirmani </h1> <p class="desc"></p> </header> <article> <div class="profile float-right"> <figure> <picture> <source class="responsive-img-srcset" srcset="/assets/img/profile-2.JPG" sizes="(min-width: 990px) 288.0px, (min-width: 576px) 30vw, 95vw"> <img src="/assets/img/profile-2.JPG?8e2fe42d85dea2ce7df0183b708b6ba3" class="img-fluid z-depth-1 rounded" width="100%" height="auto" alt="profile-2.JPG" loading="eager" onerror="this.onerror=null; $('.responsive-img-srcset').remove();"> </source></picture> </figure> </div> <div class="clearfix"> <h1 id="hi-there-">Hi there! 👋🏼</h1> <p>I love turning <strong>data</strong> into stories that <code class="language-plaintext highlighter-rouge">matter</code>, especially in fields where <code class="language-plaintext highlighter-rouge">sensitive information</code> demands <code class="language-plaintext highlighter-rouge">thoughtful</code> handling and <code class="language-plaintext highlighter-rouge">innovative</code> solutions. I’m driven by the challenge of making <code class="language-plaintext highlighter-rouge">data</code> useful while navigating the <strong>ethical, legal, and practical complexities</strong> of working with it.</p> <p>Most recently, I completed a <code class="language-plaintext highlighter-rouge">double PhD</code> in Belgium 🇧🇪 at <code class="language-plaintext highlighter-rouge">KU Leuven</code> and <code class="language-plaintext highlighter-rouge">Hasselt University</code>, where I worked on making <strong>real-world data (RWD)</strong> more <code class="language-plaintext highlighter-rouge">accessible</code> and <code class="language-plaintext highlighter-rouge">actionable</code> to derive meaningful <code class="language-plaintext highlighter-rouge">insights</code> from it.</p> <p>But let me tell you, working with data isn’t as <code class="language-plaintext highlighter-rouge">straightforward</code> as it sounds. It often feels like trying to solve a <code class="language-plaintext highlighter-rouge">jigsaw puzzle</code>, but this isn’t your typical puzzle. Imagine the pieces are <code class="language-plaintext highlighter-rouge">scattered</code> across different locations, some of them <code class="language-plaintext highlighter-rouge">locked away</code> in drawers labeled <strong>“private”</strong>, and others so <code class="language-plaintext highlighter-rouge">rare</code> they might as well be <code class="language-plaintext highlighter-rouge">one-of-a-kind</code>. Now, add a rule: you’re <code class="language-plaintext highlighter-rouge">not allowed</code> to move any pieces from their <code class="language-plaintext highlighter-rouge">original location</code>. That’s what working with data in fields like <strong>rare diseases</strong> or <strong>low-prevalence conditions</strong> feels like. <code class="language-plaintext highlighter-rouge">Every single piece matters</code>, <em>but putting them together is far from simple</em>.</p> <blockquote> <p>You’d think the solution would be <code class="language-plaintext highlighter-rouge">straightforward</code>: gather all the data into one place and get to work.</p> </blockquote> <p>But in reality, <strong>centralizing data</strong> is often out of the question. <strong>Privacy concerns</strong>, <strong>ethical dilemmas</strong>, <strong>data ownership rules</strong>, and layers of <strong>administrative hurdles</strong> stand in the way. It’s like trying to build the <code class="language-plaintext highlighter-rouge">puzzle</code> while someone keeps reminding you, <em>“You can’t touch the pieces”.</em></p> <p>So, how do we <code class="language-plaintext highlighter-rouge">solve</code> this? That’s where <strong>Federated Learning (FL)</strong> comes in.</p> <blockquote> <p>Think of FL as a way to build the puzzle <code class="language-plaintext highlighter-rouge">together</code>, but with a twist: <code class="language-plaintext highlighter-rouge">everyone</code> works on their pieces <code class="language-plaintext highlighter-rouge">separately</code>, sharing just <code class="language-plaintext highlighter-rouge">enough hints</code> to complete the bigger picture. With FL, <strong>machine learning (ML)</strong> models can be trained on <code class="language-plaintext highlighter-rouge">decentralized</code> data without ever <code class="language-plaintext highlighter-rouge">moving</code> the data itself. It’s a bit like a <strong>long-distance relationship</strong>, <code class="language-plaintext highlighter-rouge">collaborating</code> while keeping what’s personal <code class="language-plaintext highlighter-rouge">safe</code> and <code class="language-plaintext highlighter-rouge">secure</code>. This approach doesn’t just safeguard privacy; <code class="language-plaintext highlighter-rouge">it opens doors</code>. Organizations can <code class="language-plaintext highlighter-rouge">work together</code> without worrying about <em>sensitive information leaving their walls</em>, unlocking <code class="language-plaintext highlighter-rouge">insights</code> that were once impossible to achieve. My research focused on <code class="language-plaintext highlighter-rouge">designing</code> and <code class="language-plaintext highlighter-rouge">implementing</code> FL techniques to tackle exactly these kinds of <code class="language-plaintext highlighter-rouge">challenges</code>, bringing together <strong>innovation</strong> and <strong>practicality</strong> to make this futuristic idea a reality.</p> </blockquote> <div style="text-align: center; width: 100%; margin: 0 auto;"> <img src="/assets/img/banner.svg" alt="Decorative Banner" style="width: 100%; height: auto; display: block; border: none; padding: 0; margin: 0;"> </div> <h2 id="why-i-do-what-i-do-">Why I Do What I Do 👨🏻‍💻</h2> <p>The world is full of complex problems, and I believe the best solutions come from <strong>collaboration</strong>. But collaboration isn’t always easy, especially when sensitive data is involved. That’s why I love combining <strong>technical innovation</strong> with <strong>practical problem-solving</strong> to create tools that make working together possible—even when the odds are stacked against us. Whether it’s improving global data-sharing pipelines or designing tools for personalized predictions, I focus on creating solutions that are <strong>inclusive, accessible, and meaningful</strong>.</p> <p>Here are some <strong>highlights of my work</strong> (check out more details on the <a href="https://ashkan-pirmani.github.io/projects">projects page</a>):</p> <ul> <li>Built a <strong>federated, research-agnostic data analysis pipeline</strong> for the <strong>Global Data Sharing Initiative</strong> on COVID-19 and MS, contributing to one of the <strong>most comprehensive datasets</strong> for these conditions. 🌍📊</li> <li>Developed a <strong>new federated learning approach</strong> that enabled ML models to adapt to local datasets, significantly improving predictions like <strong>disability progression</strong> in MS. 🚀</li> <li>Introduced the concept of a <strong>“degree of federation”</strong>, offering organizations a flexible way to balance <strong>privacy</strong>, <strong>practicality</strong>, and <strong>collaboration</strong>. 🎯</li> <li>Created <strong>FL4E (Federated Learning For Everyone)</strong>, a framework bridging <strong>centralized</strong> and <strong>decentralized data analysis</strong> for real-world applications. 🔐🌐</li> <li>Pioneered a study that predicted <strong>disability progression</strong> in MS for over <strong>26,000 patients</strong>, using one of the <strong>largest routine clinical datasets</strong> available—all while keeping data secure. 🧠✨</li> </ul> <hr> <h2 id="lets-connect-">Let’s Connect! 🌟</h2> <p>I’m always excited to collaborate with people who share my passion for turning <strong>data into insights</strong> that make a difference. If you’re working on something where real-world data and <strong>AI/ML</strong> could play a role—whether it’s in healthcare, finance, or beyond—I’d love to chat and explore ways we can team up to create meaningful impact. 😊</p> </div> <h2> <a href="/news/" style="color: inherit">news</a> </h2> <div class="news"> <div class="table-responsive"> <table class="table table-sm table-borderless"> <tr> <th scope="row" style="width: 20%">Nov 29, 2024</th> <td> <a class="news-title" href="/news/announcement_1/">🎓 Dr² (Doctor Squared) – Yes, you heard it right! Click on me for more detailed info! 💡</a> </td> </tr> <tr> <th scope="row" style="width: 20%">Sep 18, 2024</th> <td> <h3 id="-ectrims-2024">🧠 <strong>ECTRIMS 2024</strong> </h3> <ul> <li>🗓️ <strong>When</strong>: September 2024</li> <li>📍 <strong>Where</strong>: Copenhagen, Denmark 🇩🇰</li> <li>🎤 <strong>What</strong>: Presented an <strong>abstract</strong> and <strong>poster</strong> titled:<br> <em>“Transforming Multiple Sclerosis Research: Advancing Disability Progression Insights through Practical and Precise Federated Learning using Real-World Data”</em> 🩺📊</li> <li>💡 Focus: Showcased the potential of <strong>federated learning</strong> for advancing insights into disability progression in Multiple Sclerosis using <strong>Real-World Data</strong>.</li> </ul> </td> </tr> <tr> <th scope="row" style="width: 20%">Aug 20, 2024</th> <td> <h3 id="-mie-2024">💡 <strong>MIE 2024</strong> </h3> <ul> <li>🗓️ <strong>When</strong>: August 2024</li> <li>📍 <strong>Where</strong>: Athens, Greece 🇬🇷</li> <li>🎤 <strong>What</strong>: Presented a <strong>paper</strong> titled:<br> <em>“Unlocking the Power of Real-World Data: A Framework for Sustainable Healthcare”</em> 🏥🌍</li> <li>💡 Focus: Proposed a practical framework to leverage <strong>Real-World Data</strong> for achieving <strong>sustainable healthcare systems</strong> and driving impactful insights.</li> </ul> </td> </tr> </table> </div> </div> <h2> <a href="/publications/" style="color: inherit">selected publications</a> </h2> <div class="publications"> <ol class="bibliography"> <li> <div class="row"> <div class="col col-sm-2 abbr"> <abbr class="badge rounded w-100">Federated Learning</abbr> </div> <div id="pirmani2024accessible" class="col-sm-8"> <div class="title">Accessible ecosystem for clinical research (federated learning for everyone): development and usability study</div> <div class="author"> <em>Ashkan Pirmani</em>, Martijn Oldenhof, Liesbet M Peeters, and <span class="more-authors" title="click to view 2 more authors" onclick=" var element=$(this); element.attr('title', ''); var more_authors_text=element.text() == '2 more authors' ? 'Edward De Brouwer, Yves Moreau' : '2 more authors'; var cursorPosition=0; var textAdder=setInterval(function(){ element.html(more_authors_text.substring(0, cursorPosition + 1)); if (++cursorPosition == more_authors_text.length){ clearInterval(textAdder); } }, '10'); ">2 more authors</span> </div> <div class="periodical"> <em>JMIR Formative Research</em>, 2024 </div> <div class="periodical"> </div> <div class="links"> <a class="abstract btn btn-sm z-depth-0" role="button">Abs</a> <a href="https://doi.org/10.2196/55496" class="btn btn-sm z-depth-0" role="button" rel="external nofollow noopener" target="_blank">DOI</a> </div> <div class="badges"> <a href="https://scholar.google.com/citations?view_op=view_citation&amp;hl=en&amp;user=RC2DM7kAAAAJ&amp;citation_for_view=RC2DM7kAAAAJ:YOwf2qJgpHMC" aria-label="Google Scholar link" role="button" rel="external nofollow noopener" target="_blank"> <img src="https://img.shields.io/badge/scholar-2-4285F4?logo=googlescholar&amp;labelColor=beige" alt="2 Google Scholar citations"> </a> </div> <div class="abstract hidden"> <p>Background: The integrity and reliability of clinical research outcomes rely heavily on access to vast amounts of data. However, the fragmented distribution of these data across multiple institutions, along with ethical and regulatory barriers, presents significant challenges to accessing relevant data. While federated learning offers a promising solution to leverage insights from fragmented data sets, its adoption faces hurdles due to implementation complexities, scalability issues, and inclusivity challenges. Objective: This paper introduces Federated Learning for Everyone (FL4E), an accessible framework facilitating multistakeholder collaboration in clinical research. It focuses on simplifying federated learning through an innovative ecosystem-based approach. Methods: The “degree of federation” is a fundamental concept of FL4E, allowing for flexible integration of federated and centralized learning models. This feature provides a customizable solution by enabling users to choose the level of data decentralization based on specific health care settings or project needs, making federated learning more adaptable and efficient. By using an ecosystem-based collaborative learning strategy, FL4E encourages a comprehensive platform for managing real-world data, enhancing collaboration and knowledge sharing among its stakeholders. Results: Evaluating FL4E’s effectiveness using real-world health care data sets has highlighted its ecosystem-oriented and inclusive design. By applying hybrid models to 2 distinct analytical tasks—classification and survival analysis—within real-world settings, we have effectively measured the “degree of federation” across various contexts. These evaluations show that FL4E’s hybrid models not only match the performance of fully federated models but also avoid the substantial overhead usually linked with these models. Achieving this balance greatly enhances collaborative initiatives and broadens the scope of analytical possibilities within the ecosystem. Conclusions: FL4E represents a significant step forward in collaborative clinical research by merging the benefits of centralized and federated learning. Its modular ecosystem-based design and the “degree of federation” feature make it an inclusive, customizable framework suitable for a wide array of clinical research scenarios, promising to revolutionize the field through improved collaboration and data use. Detailed implementation and analyses are available on the associated GitHub repository.</p> </div> </div> </div> </li> <li> <div class="row"> <div class="col col-sm-2 abbr"> <abbr class="badge rounded w-100">GDSI</abbr> </div> <div id="pirmani2023journey" class="col-sm-8"> <div class="title">The Journey of Data Within a Global Data Sharing Initiative: A Federated 3-Layer Data Analysis Pipeline to Scale Up Multiple Sclerosis Research</div> <div class="author"> <em>Ashkan Pirmani</em>, Edward De Brouwer, Lotte Geys, and <span class="more-authors" title="click to view 4 more authors" onclick=" var element=$(this); element.attr('title', ''); var more_authors_text=element.text() == '4 more authors' ? 'Tina Parciak, Yves Moreau, Liesbet M Peeters, others' : '4 more authors'; var cursorPosition=0; var textAdder=setInterval(function(){ element.html(more_authors_text.substring(0, cursorPosition + 1)); if (++cursorPosition == more_authors_text.length){ clearInterval(textAdder); } }, '10'); ">4 more authors</span> </div> <div class="periodical"> <em>JMIR Medical Informatics</em>, 2023 </div> <div class="periodical"> </div> <div class="links"> <a class="abstract btn btn-sm z-depth-0" role="button">Abs</a> <a href="https://doi.org/10.2196/48030" class="btn btn-sm z-depth-0" role="button" rel="external nofollow noopener" target="_blank">DOI</a> </div> <div class="badges"> <a href="https://scholar.google.com/citations?view_op=view_citation&amp;hl=en&amp;user=RC2DM7kAAAAJ&amp;citation_for_view=RC2DM7kAAAAJ:kNdYIx-mwKoC" aria-label="Google Scholar link" role="button" rel="external nofollow noopener" target="_blank"> <img src="https://img.shields.io/badge/scholar-2-4285F4?logo=googlescholar&amp;labelColor=beige" alt="2 Google Scholar citations"> </a> </div> <div class="abstract hidden"> <p>Background: Investigating low-prevalence diseases such as multiple sclerosis is challenging because of the rather small number of individuals affected by this disease and the scattering of real-world data across numerous data sources. These obstacles impair data integration, standardization, and analysis, which negatively impact the generation of significant meaningful clinical evidence. Objective: This study aims to present a comprehensive, research question–agnostic, multistakeholder-driven end-to-end data analysis pipeline that accommodates 3 prevalent data-sharing streams: individual data sharing, core data set sharing, and federated model sharing. Methods: A demand-driven methodology is employed for standardization, followed by 3 streams of data acquisition, a data quality enhancement process, a data integration procedure, and a concluding analysis stage to fulfill real-world data-sharing requirements. This pipeline’s effectiveness was demonstrated through its successful implementation in the COVID-19 and multiple sclerosis global data sharing initiative. Results: The global data sharing initiative yielded multiple scientific publications and provided extensive worldwide guidance for the community with multiple sclerosis. The pipeline facilitated gathering pertinent data from various sources, accommodating distinct sharing streams and assimilating them into a unified data set for subsequent statistical analysis or secure data examination. This pipeline contributed to the assembly of the largest data set of people with multiple sclerosis infected with COVID-19. Conclusions: The proposed data analysis pipeline exemplifies the potential of global stakeholder collaboration and underlines the significance of evidence-based decision-making. It serves as a paradigm for how data sharing initiatives can propel advancements in health care, emphasizing its adaptability and capacity to address diverse research inquiries.</p> </div> </div> </div> </li> <li> <div class="row"> <div class="col col-sm-2 abbr"> <abbr class="badge rounded w-100">GDSI</abbr> </div> <div id="simpson2022updated" class="col-sm-8"> <div class="title">Updated results of the COVID-19 in MS global data sharing initiative: anti-CD20 and other risk factors associated with COVID-19 severity</div> <div class="author"> Steve Simpson-Yap, <em>Ashkan Pirmani</em>, Tomas Kalincik, and <span class="more-authors" title="click to view 8 more authors" onclick=" var element=$(this); element.attr('title', ''); var more_authors_text=element.text() == '8 more authors' ? 'Edward De Brouwer, Lotte Geys, Tina Parciak, Anne Helme, Nick Rijke, Jan A Hillert, Yves Moreau, others' : '8 more authors'; var cursorPosition=0; var textAdder=setInterval(function(){ element.html(more_authors_text.substring(0, cursorPosition + 1)); if (++cursorPosition == more_authors_text.length){ clearInterval(textAdder); } }, '10'); ">8 more authors</span> </div> <div class="periodical"> <em>Neurology: Neuroimmunology &amp; Neuroinflammation</em>, 2022 </div> <div class="periodical"> </div> <div class="links"> <a class="abstract btn btn-sm z-depth-0" role="button">Abs</a> <a href="https://doi.org/10.1212/nxi.0000000000200021" class="btn btn-sm z-depth-0" role="button" rel="external nofollow noopener" target="_blank">DOI</a> </div> <div class="badges"> <span class="__dimensions_badge_embed__" data-doi="10.1212/nxi.0000000000200021" data-style="small_rectangle" data-legend="hover-right" style="margin-bottom: 3px;"></span> <a href="https://scholar.google.com/citations?view_op=view_citation&amp;hl=en&amp;user=RC2DM7kAAAAJ&amp;citation_for_view=RC2DM7kAAAAJ:roLk4NBRz8UC" aria-label="Google Scholar link" role="button" rel="external nofollow noopener" target="_blank"> <img src="https://img.shields.io/badge/scholar-46-4285F4?logo=googlescholar&amp;labelColor=beige" alt="46 Google Scholar citations"> </a> </div> <div class="abstract hidden"> <p>Background and Objectives: Certain demographic and clinical characteristics, including the use of some disease-modifying therapies (DMTs), are associated with severe acute respiratory syndrome coronavirus 2 infection severity in people with multiple sclerosis (MS). Comprehensive exploration of these relationships in large international samples is needed. Methods: Clinician-reported demographic/clinical data from 27 countries were aggregated into a data set of 5,648 patients with suspected/confirmed coronavirus disease 2019 (COVID-19). COVID-19 severity outcomes (hospitalization, admission to intensive care unit [ICU], requiring artificial ventilation, and death) were assessed using multilevel mixed-effects ordered probit and logistic regression, adjusted for age, sex, disability, and MS phenotype. DMTs were individually compared with glatiramer acetate, and anti-CD20 DMTs with pooled other DMTs and with natalizumab. Results: Of 5,648 patients, 922 (16.6%) with suspected and 4,646 (83.4%) with confirmed COVID-19 were included. Male sex, older age, progressive MS, and higher disability were associated with more severe COVID-19. Compared with glatiramer acetate, ocrelizumab and rituximab were associated with higher probabilities of hospitalization (4% [95% CI 1–7] and 7% [95% CI 4–11]), ICU/artificial ventilation (2% [95% CI 0–4] and 4% [95% CI 2–6]), and death (1% [95% CI 0–2] and 2% [95% CI 1–4]) (predicted marginal effects). Untreated patients had 5% (95% CI 2–8), 3% (95% CI 1–5), and 1% (95% CI 0–3) higher probabilities of the 3 respective levels of COVID-19 severity than glatiramer acetate. Compared with pooled other DMTs and with natalizumab, the associations of ocrelizumab and rituximab with COVID-19 severity were also more pronounced. All associations persisted/enhanced on restriction to confirmed COVID-19. Discussion: Analyzing the largest international real-world data set of people with MS with suspected/confirmed COVID-19 confirms that the use of anti-CD20 medication (both ocrelizumab and rituximab), as well as male sex, older age, progressive MS, and higher disability are associated with more severe course of COVID-19.</p> </div> </div> </div> </li> <li> <div class="row"> <div class="col col-sm-2 abbr"> <abbr class="badge rounded w-100">GDSI</abbr> </div> <div id="simpson2021associations" class="col-sm-8"> <div class="title">Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis</div> <div class="author"> Steve Simpson-Yap, Edward De Brouwer, Tomas Kalincik, and <span class="more-authors" title="click to view 9 more authors" onclick=" var element=$(this); element.attr('title', ''); var more_authors_text=element.text() == '9 more authors' ? 'Nick Rijke, Jan A Hillert, Clare Walton, Gilles Edan, Yves Moreau, Tim Spelman, Lotte Geys, Ashkan Pirmani, others' : '9 more authors'; var cursorPosition=0; var textAdder=setInterval(function(){ element.html(more_authors_text.substring(0, cursorPosition + 1)); if (++cursorPosition == more_authors_text.length){ clearInterval(textAdder); } }, '10'); ">9 more authors</span> </div> <div class="periodical"> <em>Neurology</em>, 2021 </div> <div class="periodical"> </div> <div class="links"> <a class="abstract btn btn-sm z-depth-0" role="button">Abs</a> <a href="https://doi.org/10.1212/WNL.0000000000012753" class="btn btn-sm z-depth-0" role="button" rel="external nofollow noopener" target="_blank">DOI</a> </div> <div class="badges"> <span class="__dimensions_badge_embed__" data-doi="10.1212/WNL.0000000000012753" data-style="small_rectangle" data-legend="hover-right" style="margin-bottom: 3px;"></span> <a href="https://scholar.google.com/citations?view_op=view_citation&amp;hl=en&amp;user=RC2DM7kAAAAJ&amp;citation_for_view=RC2DM7kAAAAJ:_FxGoFyzp5QC" aria-label="Google Scholar link" role="button" rel="external nofollow noopener" target="_blank"> <img src="https://img.shields.io/badge/scholar-250-4285F4?logo=googlescholar&amp;labelColor=beige" alt="250 Google Scholar citations"> </a> </div> <div class="abstract hidden"> <p>Background and Objectives: People with multiple sclerosis (MS) are a vulnerable group for severe coronavirus disease 2019 (COVID-19), particularly those taking immunosuppressive disease-modifying therapies (DMTs). We examined the characteristics of COVID-19 severity in an international sample of people with MS. Methods: Data from 12 data sources in 28 countries were aggregated (sources could include patients from 1–12 countries). Demographic (age, sex), clinical (MS phenotype, disability), and DMT (untreated, alemtuzumab, cladribine, dimethyl fumarate, glatiramer acetate, interferon, natalizumab, ocrelizumab, rituximab, siponimod, other DMTs) covariates were queried, along with COVID-19 severity outcomes, hospitalization, intensive care unit (ICU) admission, need for artificial ventilation, and death. Characteristics of outcomes were assessed in patients with suspected/confirmed COVID-19 using multilevel mixed-effects logistic regression adjusted for age, sex, MS phenotype, and Expanded Disability Status Scale (EDSS) score. Results: Six hundred fifty-seven (28.1%) with suspected and 1,683 (61.9%) with confirmed COVID-19 were analyzed. Among suspected plus confirmed and confirmed-only COVID-19, 20.9% and 26.9% were hospitalized, 5.4% and 7.2% were admitted to ICU, 4.1% and 5.4% required artificial ventilation, and 3.2% and 3.9% died. Older age, progressive MS phenotype, and higher disability were associated with worse COVID-19 outcomes. Compared to dimethyl fumarate, ocrelizumab and rituximab were associated with hospitalization (adjusted odds ratio [aOR] 1.56, 95% confidence interval [CI] 1.01–2.41; aOR 2.43, 95% CI 1.48–4.02) and ICU admission (aOR 2.30, 95% CI 0.98–5.39; aOR 3.93, 95% CI 1.56–9.89), although only rituximab was associated with higher risk of artificial ventilation (aOR 4.00, 95% CI 1.54–10.39). Compared to pooled other DMTs, ocrelizumab and rituximab were associated with hospitalization (aOR 1.75, 95% CI 1.29–2.38; aOR 2.76, 95% CI 1.87–4.07) and ICU admission (aOR 2.55, 95% CI 1.49–4.36; aOR 4.32, 95% CI 2.27–8.23), but only rituximab was associated with artificial ventilation (aOR 6.15, 95% CI 3.09–12.27). Compared to natalizumab, ocrelizumab and rituximab were associated with hospitalization (aOR 1.86, 95% CI 1.13–3.07; aOR 2.88, 95% CI 1.68–4.92) and ICU admission (aOR 2.13, 95% CI 0.85–5.35; aOR 3.23, 95% CI 1.17–8.91), but only rituximab was associated with ventilation (aOR 5.52, 95% CI 1.71–17.84). Associations persisted on restriction to confirmed COVID-19 cases. No associations were observed between DMTs and death. Stratification by age, MS phenotype, and EDSS score found no indications that DMT associations with COVID-19 severity reflected differential DMT allocation by underlying COVID-19 severity. Discussion: Using the largest cohort of people with MS and COVID-19 available, we demonstrated consistent associations of rituximab with increased risk of hospitalization, ICU admission, and need for artificial ventilation and of ocrelizumab with hospitalization and ICU admission. Despite the cross-sectional design of the study, the internal and external consistency of these results with prior studies suggests that rituximab/ocrelizumab use may be a risk factor for more severe COVID-19.</p> </div> </div> </div> </li> </ol> </div> <div class="social"> <div class="contact-icons"> <a href="https://github.com/ashkan-pirmani" title="GitHub" rel="external nofollow noopener" target="_blank"><i class="fa-brands fa-github"></i></a> <a href="https://www.linkedin.com/in/ashkan-p-3b8a8896/" title="LinkedIn" rel="external nofollow noopener" target="_blank"><i class="fa-brands fa-linkedin"></i></a> <a href="https://www.researchgate.net/profile/Ashkan-Pirmani#%20your%20profile%20on%20ResearchGate/" title="ResearchGate" rel="external nofollow noopener" target="_blank"><i class="ai ai-researchgate"></i></a> <a href="/feed.xml" title="RSS Feed"><i class="fa-solid fa-square-rss"></i></a> <a href="https://scholar.google.com/citations?user=RC2DM7kAAAAJ" title="Google Scholar" rel="external nofollow noopener" target="_blank"><i class="ai ai-google-scholar"></i></a> <a href="a.com" title="Work"><i class="fa-solid fa-briefcase"></i></a> </div> <div class="contact-note">For professional inquiries, please reach out to me on LinkedIn. </div> </div> </article> </div> </div> <footer class="fixed-bottom" role="contentinfo"> <div class="container mt-0"> © Copyright 2025 Ashkan Pirmani. Pulled from <a href="https://github.com/alshedivat/al-folio" rel="external nofollow noopener" target="_blank">al-folio</a> theme. Last updated: January 05, 2025. </div> </footer> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.0/dist/jquery.min.js" integrity="sha256-/xUj+3OJU5yExlq6GSYGSHk7tPXikynS7ogEvDej/m4=" crossorigin="anonymous"></script> <script src="/assets/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/mdbootstrap@4.20.0/js/mdb.min.js" integrity="sha256-NdbiivsvWt7VYCt6hYNT3h/th9vSTL4EDWeGs5SN3DA=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/masonry-layout@4.2.2/dist/masonry.pkgd.min.js" integrity="sha256-Nn1q/fx0H7SNLZMQ5Hw5JLaTRZp0yILA/FRexe19VdI=" crossorigin="anonymous"></script> <script defer src="https://cdn.jsdelivr.net/npm/imagesloaded@5.0.0/imagesloaded.pkgd.min.js" integrity="sha256-htrLFfZJ6v5udOG+3kNLINIKh2gvoKqwEhHYfTTMICc=" crossorigin="anonymous"></script> <script defer src="/assets/js/masonry.js?a0db7e5d5c70cc3252b3138b0c91dcaf" type="text/javascript"></script> <script defer src="https://cdn.jsdelivr.net/npm/medium-zoom@1.1.0/dist/medium-zoom.min.js" integrity="sha256-ZgMyDAIYDYGxbcpJcfUnYwNevG/xi9OHKaR/8GK+jWc=" crossorigin="anonymous"></script> <script defer src="/assets/js/zoom.js?85ddb88934d28b74e78031fd54cf8308"></script> <script src="/assets/js/no_defer.js?2781658a0a2b13ed609542042a859126"></script> <script defer src="/assets/js/common.js?e0514a05c5c95ac1a93a8dfd5249b92e"></script> <script defer src="/assets/js/copy_code.js?12775fdf7f95e901d7119054556e495f" type="text/javascript"></script> <script defer src="/assets/js/jupyter_new_tab.js?d9f17b6adc2311cbabd747f4538bb15f"></script> <script async src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script async src="https://badge.dimensions.ai/badge.js"></script> <script defer type="text/javascript" id="MathJax-script" src="https://cdn.jsdelivr.net/npm/mathjax@3.2.2/es5/tex-mml-chtml.js" integrity="sha256-MASABpB4tYktI2Oitl4t+78w/lyA+D7b/s9GEP0JOGI=" crossorigin="anonymous"></script> <script src="/assets/js/mathjax-setup.js?70d799092f862ad98c7876aa47712e20"></script> <script defer src="https://cdnjs.cloudflare.com/polyfill/v3/polyfill.min.js?features=es6" crossorigin="anonymous"></script> <script defer src="/assets/js/progress-bar.js?2f30e0e6801ea8f5036fa66e1ab0a71a" type="text/javascript"></script> <script src="/assets/js/vanilla-back-to-top.min.js?f40d453793ff4f64e238e420181a1d17"></script> <script>
    addBackToTop();
  </script> <script type="module" src="/assets/js/search/ninja-keys.min.js?a3446f084dcaecc5f75aa1757d087dcf"></script> <ninja-keys hidebreadcrumbs noautoloadmdicons placeholder="Type to start searching"></ninja-keys> <script src="/assets/js/search-setup.js?6c304f7b1992d4b60f7a07956e52f04a"></script> <script src="/assets/js/search-data.js"></script> <script src="/assets/js/shortcut-key.js?6f508d74becd347268a7f822bca7309d"></script> </body> </html>